Overview 12 / 48 wk Pivotal PFT vs PBO in COPD II Status: Completed Trial end date: 1969-12-31 Target enrollment: Participant gender: Summary This primary objective of this study is to compare two doses of BI 1744 CL inhalation solution delivered by the Respimat® inhaler once daily to placebo in patients with chronic obstructive pulmonary disease (COPD). Phase: Phase 3 Details Lead Sponsor: Boehringer IngelheimTreatments: Olodaterol